top of page
Executive Spotlights

Avenzo Therapeutics announces $150M Oversubscribed Financing to Advance Emerging Oncology Pipeline

San Diego, CA, March 26, 2024 (Business Wire) -- Avenzo Therapeutics concludes an oversubscribed $150 million Series A-1 financing round, bringing total capital raised to $347 million since its founding in August 2022. Led by prominent investors including NEA, Deep Track Capital, and Sofinnova Investments, this funding underscores Avenzo's commitment to advancing next-generation oncology therapeutics. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, will join Avenzo's Board of Directors, enhancing the company's strategic leadership.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial


Life Science Headlines
bottom of page